Drug-development groups and drugmakers are in disagreement over intellectual property provisions in the Trans-Pacific Partnership negotiations. An open letter was issued last week by the international charity Doctors Without Borders expressing major concern about the TPP's potential to curb access to drugs. The Pharmaceutical Research and Manufacturers of America wants to use TPP talks to raise IP standards to U.S. levels, arguing that IP protections won't block access but provide an incentive for investments. "Strong intellectual property protections in the TPP to bolster biopharmaceutical innovation will help ensure that unmet patient needs are addressed," PhRMA said.
Published in Brief: